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attached to ribosomes and can be crosslinked to eachPhiladelphia, Pennsylvania 19104
other prior to synthesis of the full-length channel subunit
(Lu et al., 2001). However, this leaves open the question
of when and in which compartment the monomeric T1Summary
domain folds to achieve its secondary and tertiary struc-
ture. Are these processes cooperative or sequential?The T1 recognition domains of voltage-gated K (Kv)
channel subunits form tetramers and acquire tertiary Do they occur inside the ribosome or after T1 emerges?
If the latter, then the T1 domain has an increased rangestructure while still attached to their individual ribo-
somes. Here we ask when and in which compartment of potential partners with which to interact. These inter-
actions may facilitate secondary and tertiary structuresecondary and tertiary structures are acquired. We
answer this question using biogenic intermediates and formation. Yet, we know virtually nothing about these
issues.recently developed folding and accessibility assays to
evaluate the status of the nascent Kv peptide both The nascent channel peptide emerges from an exit
port of the ribosomal tunnel. This tunnel begins at theinside and outside of the ribosome. A compact struc-
ture (likely helical) that corresponds to a region of PTC, located in a cavity at the interface between the
large and small ribosomal subunits, and runs throughhelicity in the mature structure is already manifest in
the nascent protein within the ribosomal tunnel. The T1 the large subunit to exit ports some distance away. The
dimensions of the tunnel are 100 A˚ in length and 10–20 A˚domain acquires tertiary structure only after emerging
from the ribosomal exit tunnel and complete synthesis in diameter (Ban et al., 2000; Beckmann et al., 2001;
Menetret et al., 2000; Nissen et al., 2000), thus makingof the T1-S1 linker. These measurements of ion chan-
nel folding within the ribosomal tunnel and its exit port it unlikely that the peptide acquires its tertiary structure
inside the ribosome but possible for secondary structurebear on basic principles of protein folding and pave the
way for understanding the molecular basis of protein to exist.
Here we apply a recently developed assay (Kosolapovmisfolding, a fundamental cause of channelopathies.
and Deutsch, 2003) to determine whether the nascent
T1 domain folds inside the ribosomal exit tunnel andIntroduction
whether the degree of folding depends on the length of
the linker between the T1 domain and the PTC. Pre-K channels are ubiquitous and critical for life. They must
be in the right place, at the right time, and in the appro- viously, we learned that T1 is folded when tethered by
a long chain to the ribosome, but not in which compart-priate density to supply the biologically requisite K
conductance to a given cell. Such a mandate is met by ment tertiary folding occurs.
To test the possibility that secondary structure existsthe collaboration between two determinants: the bio-
chemical formation of the channel and the biophysical inside the ribosomal tunnel, we have chosen a mass-
tagging accessibility strategy, pegylation (Lu andproperties of the channel. The former includes synthe-
sis, membrane integration, correct folding of the K Deutsch, 2001). We now report that segments of the T1
domain do form compact structures inside the ribo-channel protein, assembly into tetramers, and trafficking
to the cell surface. In voltage-gated K channels (Kv), somal tunnel. Furthermore, these compact regions cor-
respond to those regions in T1 Kv1 crystal structuresan N-terminal recognition domain, T1, plays a critical
role in these processes. The T1 domain, while predomi- (Kreusch et al., 1998; Minor et al., 2000) that contain
 helices.nantly a recognition agent (Li et al., 1992; Shen et al.,
1993; Xu et al., 1995), is multipurpose. It serves to dock
auxiliary proteins, which, in turn, modulate both assem- Results
bly and function (Campomanes et al., 2002; Gulbis et
al., 2000; Rettig et al., 1994; Shi et al., 1996), and to To determine how much of the nascent T1 domain must
direct Kv channels to axonal locations (Gu et al., 2003). emerge from the ribosome before it begins to acquire
Additionally, the T1 domain may modulate the gating of its tertiary structure, we used a folding assay (Kosolapov
Kv channels (Cushman et al., 2000; Kurata et al., 2002; and Deutsch, 2003) and a new analytical method (see
Minor et al., 2000), although this is still the subject of Experimental Procedures) to evaluate Pxlink, the probabil-
lively debate. Thus, T1 domain formation is pivotal dur- ity of crosslinking pairs of cysteines engineered into the
ing Kv channel ontogeny. If T1 is to serve a recognition folded monomer interfaces of the T1 domain of Kv1.3.
function, or a scaffolding function, or act as a template Pxlink is a measure of the extent of folding. The choice
to nucleate transmembrane tetramerization, then proper of engineered residues was guided by the crystal struc-
T1 tetramers must form early in biogenesis. Indeed, this ture of the isolated T1 domain of Kv1.1a (Kreusch et al.,
1998) and Kv1.2 (Minor et al., 2000), which are highly
identical to the T1 domain of Kv1.3 (e.g., 94% amino*Correspondence: cjd@mail.med.upenn.edu
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acid identity between T1 Kv1.2 and 1.3; Figures 1A and
1B). Three separate residue pairs (T69/Q112, Q72/G114,
and R83/Q136) in Kv1.3 produce consistent estimates
of Pxlink, thereby supporting this assay as a reliable mea-
sure of folding (Kosolapov and Deutsch, 2003). All three
full-length proteins are functional. T69/Q112 and Q72/
G114 are located between layers 1 and 2, and R83/Q136
is located between layers 1 and 3, according to the layer
designations of Kreusch et al. (1998). In this study, we
used primarily Q72C/G114C, depicted in Figure 1B, in
the folding assay.
Tertiary Structure Formation
A series of constructs was made in a cysteine-free Kv1.3
background that contained engineered cysteines 72C/
114C in the T1 domain. The corresponding single cys-
teine constructs were also made and used as negative
controls in the folding assays. All of these constructs
were designed to generate biogenic peptide intermedi-
ates that remain attached to the ribosome (so-called
“nascent” peptides). To do this, we made mRNA to Kv1.3
cDNA that had been truncated at selected restriction
sites and therefore lacked a stop codon (Lu et al., 2001).
As depicted in Figure 1C, this produces nascent Kv1.3
peptides with different linker lengths between the PTC
and the C terminus of T1 and different emergent lengths
of the T1 domain from the ribosomal tunnel. The BstEII-
cut construct generates the longest nascent peptide, a
total of 388 amino acids, with a linker length of 246
amino acids between the C terminus of T1 and the PTC.
The NcoI-cut construct generates the shortest nascent
peptide, a total of 142 amino acids, in which the C termi-
nus is directly attached to the PTC (zero intervening
amino acid linker length). The total number of amino
acids and the number of intervening amino acids be-
tween the PTC and any given engineered cysteine
(PTC-Cys) are given in Table 1 for all constructs.
The folding assays were performed on all the con-
structs shown in Figure 1C. As described in the Experi-
mental Procedures and shown in Figure 2, three inde-
pendent treatments are routinely carried out for any
construct containing the engineered pair of folding cys-
teines, e.g., Q72C/G114C. First, the nascent peptide was
treated with PEG-MAL to determine that both cysteines
are available for labeling with the bifunctional crosslink-
ing reagent o-phenyldimaleimide (PDM; Figure 2, lane
The NcoI restriction site is indicated above the sequence.
(B) Ribbon representation of the T1 domain of Kv1.2 taken from the
crystal structure of Minor et al. (2000). One of the four subunits is
colored blue. Residues Q72 and G114 in Kv1.3, equivalent to Q53
and G95, respectively, at the folded T1 monomer interface in Kv1.2,
are depicted as space-filling residues in one of the four subunits.
These analogous residues in Kv1.3 were mutated to cysteines for
the folding assay.
(C) Schematic of biogenic intermediates. Intermediates were gener-
ated by restriction enzymes shown to the left. The boxes represent
transmembrane segments S1-S6, and the closed circles represent
engineered cysteines Q72C and G114C. The region between the
dashed lines represents the T1 domain. In the NcoI intermediate,
Figure 1. T1 Domain Constructs the C terminus of T1 is directly attached to the PTC inside the
(A) Amino acid sequence of the T1 domain of Kv1.3 with secondary ribosome. The number of amino acids from the PTC attachment site
structure assignments derived from the highly identical Kv1.1a and (restriction site) to the C-terminal residue in T1 is given in paren-
Kv1.2 isoforms (Kreusch et al., 1998; Minor et al., 2000) shown below. theses.
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Table 1. Accessibility of Engineered Cysteines in Biogenic Intermediates
Residue NcoI (142) EcoNI (152) EarI (173) SacI (176) XbaI (201) BstEII (388)
Extent of labeling
72 0.92  0.02 (4) 0.91  0.03 (3) 0.89  0.01 (3) 0.92  0.03 (3) 0.94  0.02 (3) 0.88  0.01 (3)
83 0.90  0.01 (3) 0.85  0.03 (4) 0.80  0.00 (3) 0.80  0.02 (3) 0.85  0.03 (3) 0.81  0.01 (3)
112 0.17  0.07 (2) 0.26  0.06 (3) 0.81  0.01 (2)
114 0.26  0.04 (3) 0.38  0.04 (3) 0.53  0.03 (5) 0.77  0.02 (3) 0.78  0.04 (3) 0.82  0.02 (3)
116 0.14  0.04 (3) 0.21  0.04 (3) 0.85  0.05 (2)
136 0.35  0.03 (5) 0.28  0.02 (3) 0.71  0.01 (4) 0.65  0.01 (3) 0.78  0.03 (5) 0.83  0.02 (4)
Reactivity/maximum labeling
72 0.98/0.90 (3) 0.99/0.93 (2) 1.00/0.94 (3) 1.00/0.99 (3) 0.99/0.94 (3) 0.98/0.97 (2)
83 0.98/0.91
112 0.98/0.93
114 0.98/0.92 (3) 0.98/0.90 (2) 0.95/0.94 (3) 0.99/0.99 (3) 0.95/0.94 (3) 0.97/0.95 (2)
116 0.98/0.88
136 0.98/0.87 1.00/0.97 0.97/0.95 0.97/0.94
PTC-Cys
72 70 80 101 104 129 316
83 59 69 90 93 118 305
112 30 40 61 64 89 276
114 28 38 59 62 87 274
116 26 36 57 60 85 272
136 6 16 37 40 65 252
The total amino acid length of each peptide is given by the number in parentheses under the name of each restriction site. The extent of
labeling is the fraction of total peptide pegylated at 4 hr. Reactivity of each cysteine was determined by measuring the fraction of peptide
modified by PDM (0.5 mM, 30 min; Supplemental Table S1 [http://www.neuron.org/cgi/content/full/44/2/295/DC1]). Maximum labeling was
determined by measuring the fraction of peptide pegylated in SDS-solubilized samples (F1, Supplemental Table S1). The number of replicate
samples is given in parentheses for each mean  SEM. The length of the peptide between the PTC and the indicated cysteine (PTC-Cys)
in each biogenic intermediate is given as number of amino acids, calculated as number of the last residue included by the restriction site
minus the residue number of the engineered cysteine, e.g., 142  72  70 for residue 72 in the NcoI peptide.
1). Second, a separate sample of nascent peptide was labeled with PEG-MAL (Lu and Deutsch, 2001), and a
free peptidyl-maleimide can be labeled with PEG-SHtreated with PDM (0.5 mM) and then quenched and as-
sayed for residual free cysteines, i.e., unreacted cyste- (Kosolapov and Deutsch, 2003). If most of the protein
in lane 3 is pegylated, this indicates that little of theines, by treatment with PEG-MAL (lane 2). Third, a sepa-
rate sample of nascent peptide was treated with PDM protein is folded. If most of the protein in lane 3 is un-
pegylated, this indicates relatively more folding. For alland assayed for residual free maleimides, i.e., non-
crosslinked residues, by treatment with PEG-SH (lane 3). constructs and conditions, lane 1 shows complete label-
ing with PEG-MAL; lane 2, complete labeling of the twoAddition of PEG (pegylation) shifts the protein molecular
mass by 10 kDa. A free peptidyl-thiol group can be cysteines (two leftmost gels in top and bottom rows) or
Figure 2. Folding Assay for BstEII- and NcoI-
Cut Intermediates
(Top row) Crosslinking of BstEII-cut nascent
peptides. Leftmost gel depicts a folding
assay carried out on Q72C/G114C under non-
denaturing conditions. The second gel from
the left depicts a folding assay carried out
on Q72C/G114C after SDS pretreatment to
unfold the protein. The two rightmost gels
depict folding assays for the single cysteine
constructs, Q72C and G114C, respectively.
In all cases, nascent peptide was treated with
PEG-MAL (lane 1), or first with PDM and then
PEG-MAL (lane 2), or first with PDM and then
PEG-SH (lane 3). (Bottom row) Crosslinking
of NcoI-cut nascent peptides. The same pro-
cedures were carried out as described for the
BstEII-cut peptides. For each gel, numbers
on the left are molecular weight standards,
and numbers on the right indicate singly peg-
ylated (1), doubly pegylated (2), and unpegy-




single cysteine (two rightmost gels in top and bottom
rows) with PDM. For the shortest construct generated
by NcoI, (bottom row, leftmost gel), lane 3 indicates
that most of the nascent peptide contains free peptidyl-
maleimides, i.e., most of the peptide is unfolded. After
denaturation of the NcoI-cut peptide with SDS (second
gel from the left, bottom row), the folding assay gives
identical lanes 1–3 as those obtained under nondenatur-
ing conditions (leftmost gel). This confirms that the na-
scent NcoI-cut peptide is not folded while attached to
the ribosome. In contrast, for the BstEII-cut nascent
peptide (top row, leftmost gel), lane 3 indicates that
most of the nascent peptide contains no free peptidyl-
maleimides, i.e., the peptide is mostly folded. Pretreat-
ment with denaturing SDS produces mostly pegylated
protein in lane 3 (second gel from the left). This confirms
that the nascent BstEII-cut peptide is folded while
attached to the ribosome. The two rightmost gels in
both the top and bottom rows depict the folding assays
for the single cysteine constructs Q72C and G114C.
These experiments determine the efficiency of PEG-SH
labeling, which is included in the analysis of data to
calculate Pxlink (see Analysis of Pegylation Ladders).
Figure 3. Length-Dependent PxlinkPxlink for the smallest construct, NcoI-cut nascent
For each nascent Q72C/G114C/Kv1.3 peptide, mRNA was trans-Kv1.3, in which the C terminus of the T1 domain is at
lated and samples treated as described in Figure 2. Pxlink plotted asthe PTC, is0.05. Therefore, the NcoI peptide does not
mean  SEM for n  3 (except BstEII, n  2) were obtained using
fold inside the ribosome. In this case, the engineered the equation Pxlink  1  (2F3,AB)/(F3,A  F3,B), as derived in Analysis
cysteines 114 and 72 are 28 and 70 amino acids, respec- of Pegylation Ladders in the Experimental Procedures (filled circles).
tively, from the PTC. When a longer linker between the Negative controls (open circles, single measurements) were ob-
tained using SDS pretreatment of Q72C/G114C constructs. The xC terminus of T1 and the PTC is used, e.g., BstEII-cut
axis is the number of amino acids from the PTC attachment sitenascent Kv1.3, folding is observed (Figure 2, compare
(restriction site) to the C-terminal residue in T1.leftmost gels, top row). Pxlink is 0.6. In this case, the
114C and 72C are 274 and 316 amino acids, respec-
tively, from the PTC. Folding assays carried out on con- teine controls, gave Pxlink  0.05 for all lengths (data nottrols, e.g., single cysteine peptides and SDS-denatured shown). Finally, a third control was used in some cases:
double cysteine constructs, are consistent with folding
the nascent peptide was pretreated with SDS to dena-
of the BstEII-cut nascent Kv1.3. Similarly, a mismatched
ture the peptide (unfold the peptide) and then pegylated.
pair of cysteines, Q72C/Q136C, in the same region of
These latter negative controls are depicted as open cir-
the T1 domain, confirmed this result (data not shown).
cles in Figure 3. It is likely that the entire T1 domain inThese cysteines are farther apart in the folded tertiary
the XbaI-cut nascent peptide is outside the ribosomeT1 monomeric structure and are not crosslinked by PDM
(see accessibility measurements below), as the Pxlink for(Kosolapov and Deutsch, 2003).
XbaI, which has 59 residues between the PTC and theTo determine the length of linker necessary to permit
C terminus of T1, is similar to that obtained for nascentfolding of the T1 domain, we used the full series of
peptide containing 90 (PpumI, data not shown), 150constructs shown in Figure 1C, translated the mRNA,
(KpnI, data not shown), or 247 (BstEII) amino acid linkersand assayed folding by pegylation. Pxlink was calculated
between the PTC and C terminus of T1.according to the equations described in Analysis of Peg-
Is the inability of the short nascent peptides to foldylation Ladders in the Experimental Procedures and
due to the cramped quarters inside the ribosome? Toplotted as a function of number of amino acids between
test this possibility, we measured the extent of folding inthe PTC and the C terminus of the T1 domain (Figure
a short peptide released from the ribosome. The nascent3). Significant folding occurs when the C terminus is30
peptide (e.g., EcoNI-cut) was released using RNase,amino acids away from the PTC and is maximal and
then centrifuged, and the supernatant and pellet as-constant when this distance is60 amino acids from the
sayed for folding. We deliberately chose experimentalPTC. This is true regardless of which pair of cysteines,
conditions that generate a fraction still attached to theQ72C/G114C (Figure 3) or R83C/Q136C (data not
ribosome, which will remain in the pellet, and a fractionshown), is used in the folding assay. Several negative
released into the supernatant. In this case, we can di-controls were used in these assays. First, similar length
rectly compare folding of the released peptide to foldingconstructs containing a single cysteine (Q72C, R83C,
of the unreleased peptide in the same sample. The re-G114C, or Q136C) were pegylated subsequent to PDM
leased EconI-cut peptide folds in the supernatant (Fig-treatment. Second, for each biogenic intermediate (re-
ure 4). Moreover, the released EconI-cut peptide foldsstriction site), a mismatch of engineered pairs that do
as well as the longer XbaI-cut peptide that is eithernot crosslink was used, i.e., Q72C/Q136C (14 A˚ apart),
retained on the ribosome (pellets, RNase) or releasedas was done previously (Kosolapov and Deutsch, 2003).
These mismatched controls, as well as the single cys- (supernatant). Regardless of whether T1 in different
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BstEII, both Q72C and G114C are outside the ribosomal
tunnel and are modified with 1 mM PEG-MAL, a concen-
tration optimized for rate determinations. Quenching of
1 mM PEG-MAL is fast and complete within 30 s under
the conditions used in these experiments (data not
shown). The rate of pegylation for each of these residues
is similar, as is the rate for the shorter NcoI-cut Q72C.
G114C has a rate that is too slow to measure (gel in
Figure 5B). These rates are consistent with the assigned
locations outside versus inside the ribosome, respec-
tively, for G114C/BstEII, Q72C/BstEII, and Q72C/NcoI
versus G114C/NcoI. Relatively slower rates are consis-
tent with cysteines being at a hindered location (Lu and
Deutsch, 2001). In all cases, the final extent of labeling
was achieved by 1–2 hr.
To determine the final extent of labeling in all con-
structs from the shortest to the longest, for all cysteines,
we performed replicate experiments using either a 4 hr
and 6 hr point or a 4 hr and 20 hr point and 20 mM PEG-
MAL to ensure maximum labeling in a reasonable time.
This concentration of reagent is nonperturbing, as 19
mM free PEG (no attached MAL) in the presence of 1Figure 4. Pxlink of Released Nascent Peptide
mM PEG-MAL does not alter the final level of maximumNascent Q72C/G114C/EcoNI-cut Kv1.3 was translated and isolated
labeling, i.e., the ribosome complex, and hence peptideas described in the Experimental Procedures. Samples were treated
accessibility, is not perturbed by PEG polymer proper-with RNase (10 	g/ml) to release the peptide and then centrifuged.
Pellet and supernatant fractions were isolated and assayed for fold- ties (Bezrukov et al., 1994; Bezrukov et al., 1996; Movi-
ing. Solid gray bars represent Q72C/G114C/EconI-cut Kv1.3 sam- leanu et al., 2001).
ples assayed for folding after treatment with RNase, ribosome- NcoI nascent peptides containing either Q72C, R83C,
attached (pellet, n  4), and released (supernatant, n  4). Solid
G114C, or Q136C were pegylated (Figure 5C). Q72Cwhite bars represent Q72C/G114C/XbaI-cut Kv1.3 control samples
and R83C were completely pegylated (94% and 90%,assayed for folding after treatment with RNase, ribosome-attached
respectively). This is consistent with these residues, 70(pellet), and released (supernatant). The striped bar represents the
pelleted, ribosome-attached Q72C/G114C/XbaI-cut Kv1.3 control and 59 amino acids, respectively, from the PTC, being
that was not treated with RNase (n  3). Supernatants show no outside the ribosome. They are each available for folding
evidence of contamination from ribosome-attached protein. Data and modification. However, their corresponding part-
are mean  SEM. ners are not modified, indicating they are either inacces-
sible or unreactive. G114C is 80% unlabeled at long
incubation times. It is 28 amino acids from the PTC and
linker length constructs folds or not, the location of the
resides in the ribosomal tunnel. Residue Q136C is only
engineered cysteines is critical to the interpretation of
6 amino acids away from the PTC and is 35% pegy-
the folding data. For example, if the pair of cysteines is lated at long incubation times. It is located in the large,
located outside the ribosome but the T1 domain cannot open cleft at the entrance of the ribosomal tunnel (Harms
be crosslinked, this may suggest that T1 must be a et al., 2001; Nissen et al., 2000) and is slightly accessible
minimum distance from the ribosome in order to fold. to PEG-MAL. This cleft is large enough to accommodate
Alternatively, cysteines located just outside the ribo- tRNA and antibiotics. Although residues R83C and Q72C
some may be unreactive. The latter, however, is not the may have emerged from the ribosome, residues Q136C
case, as shown in Figure 6B (see below). and G114C remain secluded inside the ribosomal tunnel.
To determine the location of the engineered cysteines, This C-terminal portion of the T1 domain is in a different
we used an accessibility assay. This assay involves compartment from the N-terminal portion, thus preclud-
mass-tagging the nascent peptide containing a single ing folding of the T1 domain, as observed above in
cysteine of the engineered pair with PEG-MAL. This Figure 3.
modification is carried out in the absence of detergent. To study the accessibility of a given cysteine in elon-
The availability of a given cysteine depends on its loca- gated nascent Kv1.3 peptides, we used the restriction
tion. For instance, the structure of the ribosome reveals sites shown in Table 1 and Figure 6A. For example, the
a narrow exit tunnel extending the length of the large number of amino acids between the PTC and G114C is
subunit, 100 A˚ from the PTC to the exit port (Figure 28, 38, 59, 62, 87, and 274 for NcoI, EcoN I, EarI, SacI,
5A). The width of the tunnel varies from 10 A˚ to a XbaI, and BstEII, respectively (also see Figure 1C). With
maximum of 20 A˚ near the exit port. PEG-MAL cannot increasing linker length (PTC-G114C), the relative
penetrate deeply into the tunnel, which is only freely amount of pegylation increases. As shown in Figure 6B,
accessible to small molecules (see Figure 6B, below). significant modification (38% pegylated) of cysteine 114
Thus, both kinetics and final extent of pegylation of occurs after 38 amino acids have been synthesized be-
single engineered cysteines should reflect relative ac- tween the PTC and G114C and is completely accessible
cessibility. We began by measuring the kinetics of modi- (77%) when 62 amino acids have been synthesized
fication of Q72C and G114C, engineered separately into between the PTC and G114C. This corresponds to a
peptide in which all of the T1-S1 linker has been synthe-both NcoI and BstEII (Figure 5B). In the longer construct,
Neuron
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Figure 5. Accessibility of Engineered T1 Cysteines
(A) The path through the ribosome. The large ribosomal subunit is shown in blue; the small subunit is in magenta. The nascent peptide is red;
the PTC is black. The ribosomal exit tunnel is 100 
 20 A˚, according to cryo-EM structures (Ban et al., 2000; Beckmann et al., 2001; Menetret
et al., 2000; Nissen et al., 2000).
(B) Pegylation time course of single T1 cysteines 72 and 114 in BstEII-cut (top) and NcoI-cut (bottom) Kv1.3 nascent peptide. Translation
products were incubated with PEG-MAL (1 mM), quenched, and assayed on a gel (two leftmost panels, top and bottom rows), as described
previously (Lu and Deutsch, 2001). (Far right panels) Pegylation data shown in the left gel panels were calculated as cpm in the upper band
(1) divided by the sum of the cpm in both upper and lower bands (0, 1), plotted at the indicated times as fraction of peptide pegylated (Q72C,
circle; G114C, triangle), and fit to a double exponential function. In the longer BstEII construct, Q72C has modification rate constants of 9.3 
3.5 and 0.5  0.2 M1s1(n  2), whereas G114C has rate constants of 12.7  3.1 and 0.8  0.1 M1s1 (n  3). In the shorter NcoI construct,
Q72C rate constants are 14.0  2.6 and 2.2  0.2 M1s1 (n  2). Rate constants are means  SEM for n  3 or average error for n  2.
(C) Extent of pegylation of single T1 cysteines 72, 83, 114, and 136 in NcoI-cut nascent peptide. Duplicate lanes for each residue show samples
incubated with PEG-MAL (20 mM) for 4 and 6 hr. Gels were 12% NUPAGE Bis-Tris with MOPS running buffer. Numbers to the left of the gels
are MW standards; numbers to the right indicate unpegylated (0) and singly pegylated (1) protein.
sized and the T1 domain is completely out of the tunnel. assay (e.g., G114C NcoI and EconI) show efficient PDM
labeling (Supplemental Table S1, F1 and F2 [http://www.In this case, the cysteines in each folding assay pair are
in the same cytosolic compartment and thus capable neuron.org/cgi/content/full/44/2/295/DC1]; Table 1, see
Reactivity). Thus, the reason for failure to crosslink isof folding (see Figure 3). Q136C, near the PTC in the
NcoI-cut construct, is relatively inaccessible (30% not due to a failure of the cysteines to either ionize or
sterically accommodate PDM, but rather to a distance,pegylated) until it emerges at the distal end of the ribo-
somal exit tunnel and saturates at 80% pegylation orientation, and/or flexibility limitation of the pair of cys-
teines.(Table 1). Those cysteines that cannot be pegylated
efficiently are still reactive, but are relatively inaccessible To confirm the relative inaccessibility in the region of
G114C in the EconI-cut Kv1.3, we studied separatelyto PEG-MAL. This is shown in Figure 6B by the 90%
labeling for G114C by PDM, a small cysteine reagent Q112C and R116C (Table1), as well as two double cys-
teine constructs (see below). In the former case, pegyla-that gets into the tunnel and has a fast reaction rate
in an aqueous environment at 4C (500 M1s1, J.M. tion of the cysteines in the EcoNI-cut Kv1.3 was 26%,
whereas pegylation of the same cysteines in the BstEII-Robinson and C.D., unpublished data). Note that those
constructs that could not be crosslinked in the folding cut Kv1.3 was 81%. These results are similar to those
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301
Figure 6. Accessibility of G114C
(A) Extent of pegylation of G114C in successively longer nascent peptides. Nascent peptides attached to the PTC at the indicated restriction
sites were treated with 20 mM PEG-MAL for 4 hr and 20 hr (pair of lanes for each construct) at 4C and fractionated on a 4%–12% LDS-
NUPAGE Bis-Tris gel with MOPS running buffer. The upper band in each lane represents pegylated peptide; the lower band in each lane
represents unpegylated peptide. Numbers to the left are molecular weight standards. See Table 1 for total length (# of amino acids) and
distance between PTC and 114C (# of amino acids).
(B) Length-dependent fraction of modified peptide for G114C. The fraction of singly pegylated peptide (black circles) was calculated as
described in Figure 5B. Reactivity of G114C is indicated for each peptide by the fraction of peptide modified by PDM (triangles), obtained
from experiments similar to those described in Figure 2 (calculated from lanes 1 and 2). Maximal pegylation of G114C for each peptide
(inverted triangles) was determined from samples obtained from experiments similar to those described in Figure 2, lane 1. A control, Q72C,
that is always outside the ribosome in all constructs, is included (red circles, top x axis in red) for comparison with G114C. Data are mean 
SEM (n  3 for 20 of the 24 data points shown, see Table 1 for details).
(C) Rationale for secondary structure determination. A cysteine (yellow circle) located in a helical region of peptide (left, red line) inside the
ribosomal tunnel (large oval,100 A˚ length) will be relatively inaccessible to PEG-MAL, whereas if that same cysteine is located in an extended
region of peptide (right, red line), it will reside outside the ribosome and be relatively accessible to PEG-MAL.
(D) Fraction of peptide modified for Q112C/EcoNI-cut and R116C/EcoNI-cut constructs. The solid gray bars represent extent of pegylation
(n  3). Bars with upward (left-to-right) diagonal lines are the fraction labeled with PDM (n  2 for Q72C, 1 for R116C and Q112C), a measure
of the reactivity of the cysteine. Bars with downward diagonal lines are derived from SDS pretreatment followed by pegylation (n  2 for
Q72C, 1 for R116C and Q112C), a measure of maximal fractional pegylation. The unfilled bar is a BstEII pegylation control (n  3 for Q72C,
2 for R116C and Q112C), representing long chain peptides in which the cysteine is outside of the ribosomal tunnel and accessible. Q72C/
EcoNI-cut data are included for comparison; Q72C is outside of the ribosome and accessible in all-length nascent peptides (NcoI to BstEII).
Data are mean  SEM (n  3) or average deviation where applicable (n  2).
obtained with G114C, indicating that this region of na- therefore reflect the secondary structure of the nascent
peptide (Hardesty and Kramer, 2001; Kramer et al.,scent Kv1.3 is relatively hindered in the shorter con-
structs and more available in the long construct. 2001). For example, an extended conformation would
require only 30 amino acids to traverse 100 A˚, whereas
an  helix would require 67 amino acids. Because theProbing Compact Structure Formation
Accessibility determinations contain additional informa- mature isolated T1 domain has discrete segments of
both  and  conformations (Bixby et al., 1999; Kreuschtion that can be used to estimate when and where com-
paction, possibly reflecting secondary structure, occurs et al., 1998; Minor et al., 2000), we can ask whether
these segments begin to form a more compact (possibly(Figure 6C). This estimate is based on the premise that
a fully extended peptide occupies 3.4 A˚/amino acid, helical) structure inside the ribosomal tunnel. The dimen-
sions of the ribosomal tunnel may preclude tertiarywhereas an  helix occupies 1.5 A˚/amino acid (Creighton,
1993). Given the dimensions of the ribosomal tunnel structure formation, as indicated by Figures 3 and 4,
but could be permissive for secondary structure forma-(100 A˚ 
 10–20 A˚), the length of the protein when it
first emerges from the ribosome at the exit site should tion (the diameter of an  helix is 10 A˚).
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To address this issue, we compared the fraction pegy- Herein we describe the compartments in which struc-
lated to the predicted pegylation for an extended confor- ture is acquired for a Kv channel domain. We draw two
mation and an  helix. Our data are consistent with major conclusions. First, the T1 domain acquires tertiary
helix formation inside the ribosome. The following four structure only after emerging from the ribosomal exit
experimental results support this conclusion. First, tunnel. Second, the T1 domain sequence already starts
G114C in the EcoN I-cut nascent peptide is 38 amino to acquire a more compact, perhaps helical, structure
acids from the PTC (Table1, Figure 6B). If the peptide is while still inside the ribosomal tunnel.
in an all-extended conformation, then the total distance
spanned would be 129 A˚ and the cysteine would be Tertiary Structure
outside the ribosome and available for pegylation. How- Our results show that the primary determinant of Pxlink
ever, it is only 38% pegylated, only 46% of its maximum is distance/orientation, which is dictated by the proba-
labeling efficiency (82% for BstEII-cut Kv1.3 nascent bility of tertiary folding of the peptide. Thus, a low Pxlink
peptide), suggesting that some compact structure must for short peptides and a higher Pxlink for long peptides
exist inside the ribosome. Second, G114C in EarI-cut represents unfolded and folded nascent peptide, re-
nascent peptide is 62 amino acids from the PTC, pre- spectively. In the case of intermediate length nascent
dicting a length of 211 A˚ for the all-extended conforma- peptides, T1 is partially folded. Either some fraction of
tion and complete pegylation. However, this cysteine is T1 is completely folded and the rest is completely un-
only 53% pegylated. Third, two other residues in the folded, or 100% of T1 is partially folded. We cannot
vicinity of G114C, Q112C and R116C in EcoN I-cut pep- easily distinguish between these possibilities.
tide, are also pegylated 26% (Figure 6D), whereas an To interpret the apparent length dependence of fold-
all-extended structure in this region predicts that these ing, we had to locate each cysteine of the engineered
residues would be 136 and 122 A˚, respectively, in length pair in each nascent peptide. This identifies the com-
and therefore easily accessible and pegylated. As with partment in which folding occurs. If the cysteines are in
G114C EcoNI, the low pegylation is not due to decreased different compartments, then tertiary folding is pre-
reactivity (Table1, Reactivity). Fourth, a R101C/D105C cluded. If they are in the same compartment yet the
construct in NcoI is only 19% pegylated, while it is 78% domain does not fold, then we might speculate that
pegylated in the BstEII-cut construct (data not shown). another factor is responsible. We therefore determined
In the NcoI peptide, R101C and D105C are 41 and 37 the approximate compartment location of each cysteine
amino acids away from the PTC, respectively, predicting using pegylation in an accessibility assay. We have pre-
distances of 62 A˚ and 56 A˚ if the peptide is all helix viously validated the pegylation method to determine
and 139 A˚ and 126 A˚, respectively, if the peptide is all- the membrane topology of Kv1.3 (Lu and Deutsch, 2001)
extended. In the BstEII peptide, 101C and 105C are 287 and refer the reader to this paper for a more comprehen-
and 283 residues away from the PTC,400 A˚ regardless sive discussion of the advantages, disadvantages, and
of the intervening secondary structure, and therefore caveats of this approach.
always available for pegylation. These results demon-
The pegylation assay depends on the availability of
strate that a compact secondary structure exists within
the SH group, its reactivity, and the stability of the PEG
the ribosomal exit tunnel.
adduct. The latter parameter is not an issue because
the maleimide-cysteine bond is a stable, covalent link-Discussion
age. Nor is reactivity, which is governed by the pKa of
the cysteine and the local pH, as we measured reactivityHow does a Kv channel acquire its secondary, tertiary,
for each residue both inside and outside of the ribosomeand quaternary structures? Given the polytopic and
using a small molecular weight maleimide and found itoligomeric nature of ion channels, composed of many
relatively invariant. Thus, differences in pegylation re-biogenic and functional domains (Tu et al., 2000), this
flect availability, most likely due to differences in stericquestion is quite complex. The answer will form the basis
exclusion of PEG-MAL from the tunnel.for understanding normal biogenesis of ion channels as
Pores and tunnels are conceptual cousins, each capa-well as abnormal misfolding and attendant conse-
ble of housing peptide segments. For example, the S4quences for trafficking. Perturbations of biogenesis are
segment of Kv channels likely traverses a short gatingbelieved to underlie many inherited channelopathies, for
pore and can be assessed by substituted cysteine ac-example, those responsible for the majority of cases of
cessibility measurements (Larsson et al., 1996; Yangcystic fibrosis and cardiac long QT syndrome (Ashcroft,
et al., 1996). Analogously, the peptide passenger of a2000). Misfolding has been inferred mostly from ER lo-
ribosomal tunnel can be scrutinized by substituted cys-calization of the channel protein and/or decreased sur-
teine accessibility measurements and pegylation, pro-face expression of the channel. However, folding can be
viding a novel strategy to map the intra- versus extrari-more compellingly evaluated using assays specifically
bosomal location of amino acids in a nascent peptide.designed for this purpose. For example, in the case of
Tertiary folding of nascent T1 increases monotonicallytertiary folding, the assay should detect folding itself in
with the length of the PTC-T1 linker. T1 folds significantlythe nascent peptide, and not some downstream conse-
at a linker length of 30 amino acids, and folding saturatesquence such as the peptide’s ability to function. While
at a linker length of 40–60 amino acids. A similardetection of enzymatic activity has been used to assess
length-dependent folding occurs for Semliki Forest virusthe tertiary structure of nascent enzymes (Hardesty and
(SFV) capsid protease domain (Cp), in which autoproteol-Kramer, 2001; Kowarik et al., 2002), only a more direct
ysis is achieved only upon correct folding of the Cp domainassay (Kosolapov and Deutsch, 2003) permits folding
of Kv domains to be studied. (Kowarik et al., 2002). In the absence of ER membranes,
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half of the Cp peptide chains were cleaved autocatalyt- the ribosomal exit tunnel itself, and not the length of the
ically when the linker length was 39–40 amino acids, PTC-T1 linker, restricts nascent T folding. Similar results
and 52 amino acids are required for maximal cleavage, were obtained for short Cp domains, which fold upon
i.e., folding of the Cp domain. Some difference in appar- release from the ribosome (Kowarik et al., 2002). How-
ent length-dependent folding is expected for these two ever, neither the lack of crosslinking of short nascent
different proteins due to differences in secondary struc- T1 domains nor the lack of autoproteolytic activity by
ture for the Kv1.3 T1 domain versus the SFV Cp domain short Cp domains precludes folding of some elements
(see below, Secondary Structure). of these domains inside the exit tunnel.
The length dependence of tertiary folding can arise The third possible reason for length-dependent ter-
for three reasons. First, the dimensions of the ribosomal tiary folding is interaction of specific linker amino acids
exit tunnel can spatially restrict the T1 domain from with a chaperone or third-party promoter of folding. This
obtaining a tertiary structure. Second, the length of the possibility is unexplored and requires further experi-
nascent peptide can itself be critical for efficient folding. ments, e.g., replacement of the linker with different se-
Third, a specific sequence in the linker region may be quences. Finally, we note that folding of the T1 domain
necessary for interaction with a chaperone or third-party is correlated with the location of cysteine pairs in the
promoter of folding. In addition, a combination of these same extraribosomal compartment, i.e., in the cyto-
reasons may obtain. Regarding the first possibility, the plasm. Both 50% maximal accessibility and 50% folding
dimensions of the ribosomal exit tunnel, 100 A˚ long and occur at the same length of peptide (see below).
10–20 A˚ in diameter (Ban et al., 2000; Beckmann et al.,
2001; Menetret et al., 2000; Nissen et al., 2000), clearly Secondary Structure
leave little room for a peptide to fold into a tertiary struc- In the mature T1 domain, the folded monomer contains
ture. This is especially true if the peptide occupying the secondary structure, i.e.,  helices (Kreusch et al., 1998;
tunnel is in a helical conformation, which is 10 A˚ in Minor et al., 2000). Acquisition of secondary and tertiary
diameter. There would be barely enough room for a structure could be sequential or concerted events. One
single  helix in the narrowest diameter region of the possible scenario is that secondary structure evolves
tunnel and barely enough for a folded hairpin in the first while the nascent peptide resides in the ribosomal
widest diameter region of the tunnel. However, there tunnel. Accessibility measurements addressed this pos-
are two caveats. First, these ribosome structures were sibility.
obtained in the absence of nascent peptide in the tunnel. The results shown in Figure 6 and Table 1 suggest
Second, the detergents used in these studies may pre- that segments within the T1 domain form a compact
clude association of other proteins normally associated structure, likely an  helix, inside the ribosomal tunnel.
with the ribosome under native conditions in vivo. Thus, This conclusion is based on several residues (G114C in
these dimensions of the ribosomal tunnel are anatomical EcoNI and in EarI; Q112C and R116C, each in EcoNI;
dimensions of a stripped down ribosome complex. and R101C/D105C in NcoI) that are pegylated much less
Recently obtained structures of the ribosome indicate than the amount predicted if they were in an all-extended
another important consideration, namely that the ribo-
conformation, and yet are pegylated 80% in the long
somal exit tunnel is dynamic. One suggestion comes
BstEII construct in which the cysteines are outside the
from the crystal structure of the large subunit of the
tunnel (all 380 A˚ regardless of the secondary confor-
ribosome with bound macrolide antibiotic in the tunnel
mation) and thus accessible. A change in G114C acces-(Berisio et al., 2003). The macrolide induces a conforma-
sibility from25 to 80% requires 34 amino acids versustional rearrangement of a tunnel wall component. Thus,
only 6 amino acids for an all-extended control peptideour view of the ribosomal tunnel must include gating
(J. Lu and C.D., unpublished data). This is consistentmechanisms and shape changes. The other evidence
with a compact structure inside the ribosomal tunnelcomes from a cryo-EM reconstruction of the ribosome
for these regions of T1. These regions correspond towith nascent peptide trapped within the exit tunnel (Gil-
3, 4, and 5 in the T1 crystal structure (see Figurebert et al., 2004). In this case, nascent peptide appears
1A). Thus, a compact structure is already manifest in theto displace the walls of the exit tunnel and increase the
nascent protein inside the ribosome that corresponds tointernal volume of the exit tunnel. The nascent peptide,
a region of helicity in the mature structure. Whether thehowever, was not visualized well enough to discern any
conformation inside the ribosome is strictly helical ordetailed structure. A dynamic ribosome could uncramp
some other form of compact structure cannot be deter-the tunnel enough to allow for tertiary folding. However,
mined at this time.this does not appear to be the case in our study. Al-
Compaction of nascent peptide inside the ribosomethough PDM can label cysteine pairs deep within the
has been implicated previously from four types ofribosomal tunnel, it does not crosslink them. Only when
assays: protease protection, enzymatic activity of na-these pairs emerge from the tunnel can they crosslink,
scent proteins, antibody binding, and glycosylationindicative of a folded structure.
(Hardesty and Kramer, 2001; Kramer et al., 2001; Mat-To evaluate the second possible explanation for inhib-
lack and Walter, 1995; Mingarro et al., 2000). Proteaseited tertiary folding inside the ribosome in the short pep-
protection and enzymatic activity depend not only ontides (NcoI- and EcoNI-cut), i.e., cramped quarters, we
emergent length of the peptide, but also on proper ac-determined the efficiency of folding for these peptides
cess of the substrate to a correctly folded active site.released from the ribosome prior to the folding assay.
Glycosylation depends on an oligotransferase locatedFrom these studies, we draw two conclusions. First,
in the lumen of the ER and thus the entire ribosome/the short peptides are fully competent to form tertiary
structures when released from the ribosome. Second, translocon complex is evaluated as a unit. The same
Neuron
304
caveats regarding substrate-active site interactions aly appears for 136C EarI vis-a`-vis 114C EarI constructs
apply in this case as well. In the case of antibody binding, (Table1), the latter having a lower extent of pegylation.
a minimum chain length for the epitope to be exposed Two considerations account for this behavior. First, the
and recognized is required and can be used to estimate reactivities of 136C versus 114C may be different. Sec-
the conformational state of the chain inside the ribo- ond, the T1 crystal structure reveals that residues 136
some (Tsalkova et al., 1998). There is some ambiguity, and 114 are in proximity due to a tertiary fold. The latter
however, because an epitope must be correctly pre- may suggest that some folding of an intermediate length
sented to be recognized by the antibody. Thus, tertiary chain occurs in the more distal, wider parts of the exit
structure requirements may confound the apparent tunnel and may be compatible with a recent cryo-EM
chain length required for emergence. image of dynamic ribosome/nascent peptide complex
A recent study, using fluorescence resonance energy (Gilbert et al., 2004).
transfer (FRET) measurements, shows that a nascent The new view of the ribosome as a dynamic structure
transmembrane (TM) chain folds within the exit tunnel, has many implications for the role of the ribosomal tun-
while close to the PTC and all along the tunnel, regard- nel in protein biogenesis. This conformationally fickle
less of whether or not the ribosome is bound to the ER structure, complete with moving gates (Agmon et al.,
membrane (Woolhead et al., 2004). This folding occurs 2003), means that the dimensions of the tunnel and
when the nascent chain contains 20 TM residues, but its hydrophobic/hydrophilic interior may change during
not when it contains only 10 of these TM residues. In translation of a protein, masking or unmasking nonpolar
contrast, a stretch of 24 residues in a soluble secretory patches on the surface of the ribosomal tunnel. Interest-
protein, preprolactin, does not form a compact structure. ingly, Liao et al. (1997) have proposed that such regions
Transmembrane segments, however, are not the only promote folding of nonpolar stretches of nascent pep-
segments to form compact structures inside the ribo- tides via hydrophobic interactions and these regions
somal tunnel. Our data show that soluble cytoplasmic are dynamically regulated during translation. Recent 3D
domains, such as the T1 domain, can also, unlike prepro- crystal structures depict antibiotic-induced conforma-
lactin, form compact structures inside the ribosome. To tional changes in the tunnel, specifically ribosomal pro-
reconcile our findings with those of Woolhead et al., we tein L22 moves into the tunnel and blocks the elongation
note a key difference is translocation into the ER lumen. path (Berisio et al., 2003). The size of the entrance to
The T1 domain never crosses the translocon to enter the tunnel differs depending on whether the ribosomes
the lumen, whereas secretory proteins are fated to do are translating or not (Gabashvili et al., 2001) as is the
just that. Alternatively, the apparent prohibition of a sub- volume of the tunnel and accumulation of nascent pro-
class of soluble proteins, namely, secretory proteins, tein (Gilbert et al., 2004). This latter finding confers a
may not be a general injunction at all, but rather a pro- caveat on the determination of secondary structure. Nei-
tein-specific observation. Different proteins contain do- ther the accessibility measurements, the FRET measure-
mains of differing helix propensity. Indeed, it may be ments, nor any other measurements of emergent length
the inherent helix propensity of the sequence that deter- can distinguish between true helical structure and any
mines whether compact structure forms in the ribo- other compact structure. At this time, we may only dis-
somal tunnel. tinguish an extended structure from a compact struc-
Another contrasting feature is the length of putative ture. Nonetheless, we can conclude that the T1 domain
compact chain detected. Pegylation of residues G114C, of Kv channels acquires a compact structure inside the
Q112C, and R116C in the EcoNI-cut T1 nascent peptide ribosome soon after it is synthesized and before it exits
suggest that the segment residing inside the ribosome the ribosomal tunnel. Moreover, the nascent T1 domain
is compact even though the total stretch of helix in the folds efficiently into its tertiary structure only after the
mature T1 structure (Figure 1A) is too short according domain is outside of the tunnel and the T1-S1 linker has
to Woolhead et al. to form a compact structure in the
been completely synthesized.
tunnel. This segment includes an 11 amino acid helix
Channel assembly requires the acquisition of correct
(4) and an 11 amino acid helix (5) separated by 3
quaternary, tertiary, and secondary structure. Theseamino acids. Yet, we still detect compact structure. Is
events may be coupled and synchronous, one promot-this because the ribosome does not “see” the interven-
ing the other (J.M. Robinson and C.D., unpublisheding 3 amino acids and effectively senses a 22 amino
data). Similarly, association of auxiliary subunits with aacid stretch with high helix propensity? Alternatively,
channel depends on folding and assembly of the chan-Woolhead et al.’s prohibition may be protein specific.
nel subunits and may even facilitate these events (Shi etOne final comment regarding residue 136 is war-
al., 1996). Failure to associate can lead to inappropriateranted. In the NcoI-cut nascent peptide, 136C is only 6
targeting and/or function of the complex and to pathol-residues away from the PTC and is pegylated 35%,
ogy. These studies are aimed at understanding the step-presumably from the opening at the top of the tunnel
wise progression of structure acquisition of ion chan-at the interface between the small and large ribosome
nels, and they pave the way for scrutiny of the remainingsubunits (Figure 5A). This foyer is large enough to permit
Kv domains.tRNA and antibiotics to enter and does not prevent PEG-
MAL entry, although accessibility is somewhat limited.
Experimental ProceduresA longer chain (EcoN1) places 136C further into the
constricted part of the tunnel, decreasing pegylation to Constructs and In Vitro Translation
28%. Further elongation increases the pegylation, with Standard methods of bacterial transformation, plasmid DNA prepa-
a maximum pegylation of 83% for the BstEII construct. ration, and restriction enzyme analysis were used. The nucleotide
sequences of all mutants were confirmed by automated cycle se-This behavior is expected. However, an apparent anom-
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quencing performed by the DNA Sequencing Facility at the School rpm for 15 min at 4C. Each pellet was resuspended in 30 	l PBS
buffer containing 0.1 mM DTT and incubated with 1 mM PEG-MALof Medicine on an ABI 377 Sequencer using Big dye terminator
chemistry (A0BI). All mutant DNAs were sequenced throughout the at 4C for 2–180 min, sampling aliquots at appropriate times. Each
sample was quenched by addition of 100 mM DTT and subsequententire coding region. Engineered cysteines were introduced into
pSP/Kv1.3/cysteine-free (Lu et al., 2001) using QuikChange Site- incubation at room temperature for 15 min.
Directed Mutagenesis Kit as described in Kosolapov and Deutsch
(2003).
Analysis of Pegylation Ladders
Capped cRNA was synthesized in vitro from linearized templates
For any given construct, radioactive protein incubated with PEG-
using Sp6 RNA polymerase (Promega, Madison, WI). Linearized tem-
MAL or PEG-SH was detected as distinct bands on NuPAGE gels
plates for Kv1.3 translocation intermediates were generated using
and quantified using PhosphorImaging. The data were analyzed as
several restriction enzymes to produce different length DNA con-
follows. For each lane, j, of the gel, the fraction of total protein
structs lacking a stop codon (see Figure 1C). Proteins were trans-
molecules with exactly i pegylated cysteines was calculated as
lated in vitro with [35S]Methionine (2 	l/25 	l translation mixture;
10 	Ci/	l Express, Dupont/NEN Research Products, Boston, MA)
Wj (i )  cpm(i )/cpm(i ), (1)for 1 hr at 22C in a rabbit reticulocyte lysate (2 mM final [DTT])
according to the Promega Protocol and Application Guide.
where cpm(i ) is the counts per minute in the ith bin. For example,
in Figure 2, for each Kv construct with two engineered cysteines, i
Gel Electrophoresis and Fluorography ranges from 0 to 2; for each Kv construct with one engineered
All samples were treated with RNase (20 	g/ml) before loading on cysteine, i ranges from 0 to 1. If each cysteine is assumed to label
the gel. Electrophoresis was performed using the NuPAGE system to the same final extent, the fraction Fj of individual cysteines pegy-
and precast Bis-Tris 10%, 12%, or 4%–12% gels, and MOPS running lated in the jth lane is
buffer. Gels were soaked in Amplify (Amersham Corp., Arlington
Heights, IL) to enhance 35S fluorography, dried, and exposed to iWj (i )/N, (2)
Kodak X-AR film at 70C. Typical exposure times were 16–30 hr.
Quantitation of gels was carried out directly using a Molecular Dy- where N is the total number of cysteines in the protein molecule.
namic PhosphorImager (Sunnyvale, CA), which is very sensitive and For the gels in Figure 2, F1 is the fraction of individual cysteines
detects cpm that are not necessarily visualized in autoradiograms labeled by PEG-MAL (lane 1). F2 is the fraction of individual cysteines
exposed for 16–30 hr. labeled by PEG-MAL after treatment with PDM (lane 2). From lane
3, the fraction of individual cysteines that has reacted with both
Folding Assay PDM and PEG-SH is F3.
As described previously (Kosolapov and Deutsch, 2003), translation We have previously demonstrated that cysteines sufficiently far
reaction (10–20 	l) was added to 500 	l phosphate-buffered saline from one another during PDM labeling have a very low probability
(PBS, Ca-free, containing 4 mM MgCl2 [pH 7.3]) with 2 mM DTT. of being crosslinked with PDM and that crosslinking by PDM did
The suspension was centrifuged at 70,000 rpm/20 min/4C through not occur after SDS denaturation (Kosolapov and Deutsch, 2003).
a sucrose cushion (120 	l, containing 0.5 M sucrose, 100 mM KCl, In this study, we formulate a new analysis to accommodate mea-
50 mM HEPES, 5 mM MgCl2, 2 mM DTT [pH 7.5]). The pellet was surement of cysteines that reside inside the ribosomal tunnel as
resuspended in 50 or 500 	l PBS. Ortho-phenyldimaleimide (PDM; well as those residing outside. Specifically, we compare the labeling
Sigma Chemical Co.), 0.5 mM, was added to those samples to be in single cysteine constructs and double cysteine constructs and
labeled while a control sample was treated identically but in the can estimate the crosslinking efficiency as follows. Consider a pro-
absence of PDM, at0C for 30 min. No reducing agent was present tein that has one of two different cysteines (A or B). For N 1, a single
in these incubations. PDM samples used for subsequent MAL-pegy- cysteine construct with, for example, cysteine A, the probability that
lation were quenched with 10 mM -mercaptoethanol at room tem- it will be labeled by PEG-SH, F3,A, is given by the following.
perature for 10 min. Control samples, untreated with PDM, were
treated identically. A third sample was labeled with PDM but re- F3,A  Pr{A has a free maleimide}PPEG-SH,A, (3)
served for treatment with PEG-SH. Thiol reducing agents must be
avoided in PDM samples subsequently treated with PEG-SH, other- where PPEG-SH,A is the probability that cysteine A labeled with PDM
wise free maleimides will be modified and further assay with PEG- reacts with PEG-SH. F3,B is calculated similarly for cysteine B. F3,A
SH will be blocked. Samples were centrifuged at 70,000 rpm, 4C, and F3,B are determined, for example, from lane 3 of the gels in
for 15 min, resuspended in 50 	l PBS containing 1% SDS, and Figure 2 for Q72C and G114C, respectively, using Equations 1 and
incubated at room temperature for 30 min. Those samples desig- 2. The probability of labeling cysteine A in the double mutant con-
nated for pegylation with methoxy-polyethylene glycol maleimide taining both cysteine A and cysteine B, PA,AB, is as follows.
(PEG-MAL, MW 5000; Shearwater, Inc.) were treated with 10 mM
-mercaptoethanol to prevent oxidation, which inhibits pegylation. PA,AB  (fraction of non-crosslinked cysteine A’s
Samples destined for pegylation with methoxy-polyethylene-thiol labeled by PEG-SH)(fraction of cysteine A not
(PEG-SH, MW 5000; Shearwater, Inc.) received 50 	l PBS containing crosslinked to cysteine B)  F3,A(1  PxlinkA ), (4)
only 1% SDS. All SDS-treated samples were diluted with either 50
	l PBS containing PEG-MAL to give a final concentration of PEG- where PxlinkA is the fraction of cysteine A crosslinked to cysteine B.
MAL of 20 mM and 5 mM -mercaptoethanol or 50	l PBS containing Because the double mutant constructs contain one cysteine each
PEG-SH to give a final concentration of 20 mM PEG-SH. The pegyla- of A and B, PxlinkA  PxlinkB  Pxlink. Similarly, for cysteine B,
tion reaction reached a maximum, constant level by 1 hr of incuba-
tion at 4C, and the PDM reaction reached steady state by 30 min. PB,AB  F3,B(1  Pxlink ). (5)
Assuming that cysteine A and cysteine B in the double constructAccessibility Assay
behave similarly to A and B in the single constructs (Kosolapov andTranslation reaction (10–20 	l) was added to 500 	l phosphate-
Deutsch, 2003; Lu and Deutsch, 2001),buffered saline (PBS, Ca-free, containing 4 mM MgCl2 [pH 7.3]) with
2 mM DTT. The suspension was centrifuged at 70,000 rpm/20 min/
F3,AB  1⁄2(F3,A  F3,B)(1  Pxlink ). (6)4C through a sucrose cushion (120 	l, containing 0.5 M sucrose,
100 mM KCl, 50 mM HEPES, 5 mM MgCl2, 2 mM DTT [pH 7.5]). The
Here, 1⁄2(F3,A  F3,B), derived from Equation 2, represents the fractionpellet was resuspended in 100 	l PBS with 10 mM -mercaptoetha-
of non-crosslinked cysteines that are pegylated. Finally, the proba-nol at 4C for 4–22 hr and treated with 20 mM PEG-MAL.
bility of a pair of cysteines being crosslinked by PDM isThe rate constants for pegylation of selected T1 cysteines were
determined as follows. Translation reaction (5–8 	l) was diluted with
500 	l PBS and centrifuged through a sucrose cushion at 70,000 Pxlink  1  (2F3,AB)/(F3,A  F3,B). (7)
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